Skip to content
ASCELIA
AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY
En
Sv
About us
Management
Board of Directors
Therapeutic areas
Liver metastases
Gastric Cancer
Pipeline
Orviglance®
Oncoral
Partnering
Investors
Press releases
Financial reports
Presentations & articles
Events
Share information
Shareholders
Insiders
Equity research
Financial calendar
Governance
General Meeting
Articles of Association
Nomination Committee
Board of Directors
Audit Committee
Remuneration Committee
Commercialization Committee
Remuneration
Auditors
Internal control
Career
Open positions
Our values
Contact
HC Andersen – Q4 2022 highlights and Q&A
2023-02-16
Chief Executive Officer presents at HC Andersen
All
Articles
Presentations
Video
Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings".
Read our cookie policy
Settings
Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year.
Read our cookie policy
Necessary
These cookies are not optional. They are needed for the website to function.
Statistics
In order for us to improve the website's functionality and structure, based on how the website is used.
Experience
In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
Marketing
By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save
Accept all
